Trials / Completed
CompletedNCT00853086
Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
United Kingdom Haemophilia Centre Doctor's Organisation (UKHCDO) - Novo Nordisk Collaboration on NovoSeven® Post Marketing Follow-up Measures
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 139 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe. The purpose of this retrospective study is to collect additional safety information of patients with haemophilia and inhibitors who are treated with rFVIIa.
Detailed description
Non-interventional, retrospective data collection on standard treatments of haemophilia A and B patients with inhibitors in the UK.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | activated recombinant human factor VII | Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-03-02
- Last updated
- 2016-11-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00853086. Inclusion in this directory is not an endorsement.